WCLC 2026: The lung cancer drug development readouts that caught our eye
WCLC 2026: The lung cancer drug development readouts that caught our eye Labiotech.eu
Онкология
🎗️Лента новостей
Онкология
Funding Approved For New UIC Cancer Research Center
Funding Approved For New UIC Cancer Research Center Chicago YIMBY
Онкология
Scientists discover cells that cheat death and rebuild damaged tissue
Scientists discovered a population of cells that can start the process of programmed cell death, survive it, and then help rapidly rebuild damaged tissue. Their descendants become far more resistant to future damage, revealing a mechanism that could improve healing but may also help cancers return after treatment.
🎗️
Онкология
Переболевшие раком рассказали о первых настораживающих симптомах
Переболевшие раком рассказали о первых настораживающих симптомах Главный Региональный
Онкология
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) BioSpace
🎗️
Онкология
How Cancer Research Turned ‘Terminal’ Into ‘Curable’
How Cancer Research Turned ‘Terminal’ Into ‘Curable’ Eye On Sun Valley
Онкология
Раскрыт механизм, позволяющий половине всех видов рака скрываться от уничтожения
Раскрыт механизм, позволяющий половине всех видов рака скрываться от уничтожения hightech.plus
🎗️
Онкология
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer Business Wire
🎗️
Онкология
За 2 года до болезни: хирург назвал первый звоночек опасного рака — пока еще не слишком поздно
За 2 года до болезни: хирург назвал первый звоночек опасного рака — пока еще не слишком поздно Хибины.ру
Онкология
New evidence supports possible anticancer effects with GLP-1s
The inflection point has arrived. More than a dozen studies presented at ASCO Annual Meeting added to a growing volume of research that suggests GLP-1 receptor agonists may protect against several types of cancer. However, as evidence mounts, so do reminders that findings have emerged entirely from database-driven…
Онкология
New evidence supports possible anticancer effects with GLP-1s
The inflection point has arrived. More than a dozen studies presented at ASCO Annual Meeting added to a growing volume of research that suggests GLP-1 receptor agonists may protect against several types of cancer. However, as evidence mounts, so do reminders that findings have emerged entirely from database-driven…
Онкология
China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours
China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours Clinical Trials Arena
Онкология
Whole-Pelvic vs Prostate-Only Radiotherapy in High-Risk Prostate Cancer
Whole-Pelvic vs Prostate-Only Radiotherapy in High-Risk Prostate Cancer Oncodaily